|
|
||
|
|
Dr. Marc Tessier-Lavigne, Senior Vice President of Drug Discovery at Genentech, has had a distinguished scientific career in both academia and the corporate sector. In his current role at Genentech as Senior Vice President of Drug Discovery, Dr. Tessier-Lavigne oversees the in-house drug discovery teams in oncology, molecular biology, physiology and medicinal chemistry which comprise approximately two-thirds of the company's research. His current research includes elucidating mechanisms of brain wiring and other basic problems in the developmental biology of tissue growth. As an outgrowth of the aforementioned work, Dr. Tessier-Lavigne most recently has expanded his research to include brain re-wiring and regeneration as well as developmental and tumor angiogenesis. Prior to joining Genentech, Dr. Tessier-Lavigne was a Howard Hughes Medical Institute (HHMI) Investigator at Stanford University and UCSF studying the molecular cues guiding nervous system wiring. In 1994 he published two seminal Cell articles in which his research group made the groundbreaking discovery of netrins which are the chemicals responsible for axon guidance, answering a question that baffled neurobiologists for over a century. Dr. Tessier-Lavigne received his undergraduate degree in physics from McGill University and was awarded the prestigious Rhodes Scholarship to study at Oxford University where he graduated with First Class Honors in philosophy and physiology. He then went on to receive his Ph.D. in physiology from University College London and subsequently did post-doctoral fellowships at University College London and Columbia University. Dr. Tessier-Lavigne is an author on over 160 scientific journal articles and has been the recipient of numerous awards and honors during his scientific career including being elected to the National Academy of Sciences in 2005. Dr. Tessier-Lavigne has most recently received the Reeve-Irvine Research Medal and has been appointed a Fellow of the Academy of Medical Sciences, UK, the Royal Society of the UK, the American Association for the Advancement of Science, and the Royal Society of Canada. Sources: Genentech, Inc. (http://www.gene.com/gene/research/sci-profiles/research/t-lavigne) Profile in Nature Medicine (http://www.nature.com/nm/journal/v10/n1/full/nm0104-10.html) |
|
|
||
Keynote Speaker
